Refractory dissecting cellulitis of the scalp treated with adalimumab.
Dissecting cellulitis of the scalp (DCS) is a suppurative, neutrophillic dermatosis. Therapies typically provide short-term improvement and include antibiotics, prednisone, and isotretinoin, as well as radiation, surgical excision, and laser ablation. The authors report the use of the tumor necrosis factor (TNF) blocker, adalimumab, to successfully treat a 39-year-old male with a long-standing history of DCS.
Sukhatme
Smita V
SV
Tufts University School of Medicine, Boston, MA, USA.
Lenzy
Yolanda M
YM
Gottlieb
Alice B
AB
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002481:Cellulitis / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D002921:Cicatrix / Q000473:pathology; D006801:Humans; D015474:Isotretinoin / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012535:Scalp / Q000473:pathology*; D012867:Skin / Q000473:pathology*; D014409:Tumor Necrosis Factor-alpha / Q000819:agonists
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007641:Keratolytic Agents; D014409:Tumor Necrosis Factor-alpha; D015474:Isotretinoin; D000068879:Adalimumab